Michael J Silverberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2070435/publications.pdf

Version: 2024-02-01

142 papers

12,263 citations

54 h-index 26610 107 g-index

142 all docs 142 docs citations

times ranked

142

12480 citing authors

#	Article	IF	CITATIONS
1	Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada. PLoS ONE, 2013, 8, e81355.	2.5	1,111
2	Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival. New England Journal of Medicine, 2009, 360, 1815-1826.	27.0	986
3	Natural History and Possible Reactivation of Human Papillomavirus in Human Immunodeficiency Virus–Positive Women. Journal of the National Cancer Institute, 2005, 97, 577-586.	6.3	558
4	De Facto Long-term Opioid Therapy for Noncancer Pain. Clinical Journal of Pain, 2008, 24, 521-527.	1.9	527
5	Trends in longâ€ŧerm opioid therapy for chronic nonâ€cancer pain. Pharmacoepidemiology and Drug Safety, 2009, 18, 1166-1175.	1.9	484
6	Risk of Anal Cancer in HIV-Infected and HIV-Uninfected Individuals in North America. Clinical Infectious Diseases, 2012, 54, 1026-1034.	5.8	453
7	CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. Aids, 2008, 22, 841-848.	2.2	321
8	Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 39-46.	2.1	316
9	Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016. JAMA Network Open, 2020, 3, e207954.	5.9	299
10	Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons. Annals of Internal Medicine, 2018, 169, 205.	3.9	273
11	Cumulative Incidence of Cancer Among Persons With HIV in North America. Annals of Internal Medicine, 2015, 163, 507-518.	3.9	271
12	HIV infection and the risk of cancers with and without a known infectious cause. Aids, 2009, 23, 2337-2345.	2.2	252
13	HIV Infection, Immunodeficiency, Viral Replication, and the Risk of Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2551-2559.	2.5	249
14	Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. AIDS Research and Human Retroviruses, 2016, 32, 50-58.	1.1	231
15	Trends in long-term opioid therapy for noncancer pain among persons with a history of depression. General Hospital Psychiatry, 2009, 31, 564-570.	2.4	187
16	Invasive Cervical Cancer Risk Among HIV-Infected Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 405-413.	2.1	184
17	HIV Infection Status, Immunodeficiency, and the Incidence of Non-Melanoma Skin Cancer. Journal of the National Cancer Institute, 2013, 105, 350-360.	6.3	180
18	Predicting risk of cancer during HIV infection. Aids, 2013, 27, 1433-1441.	2.2	158

#	Article	lF	CITATIONS
19	Older Age and the Response to and Tolerability of Antiretroviral Therapy. Archives of Internal Medicine, 2007, 167, 684.	3.8	148
20	Weight gain among treatmentâ€naìve persons with HIV starting integrase inhibitors compared to nonâ€nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. Journal of the International AIDS Society, 2020, 23, e25484.	3.0	148
21	Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS. Aids, 2016, 30, 273-291.	2.2	144
22	Immunodeficiency and Risk of Myocardial Infarction Among HIV-Positive Individuals With Access to Care. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 160-166.	2.1	143
23	End-Stage Renal Disease Among HIV-Infected Adults in North America. Clinical Infectious Diseases, 2015, 60, 941-949.	5.8	142
24	Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States. Clinical Infectious Diseases, 2018, 66, 1230-1238.	5.8	131
25	Trends in prescribed opioid therapy for non-cancer pain for individuals with prior substance use disorders. Pain, 2009, 145, 287-293.	4.2	117
26	Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000–2010. Journal of Infectious Diseases, 2016, 214, 862-872.	4.0	116
27	Risk of cancers during interrupted antiretroviral therapy in the SMART study. Aids, 2007, 21, 1957-1963.	2.2	113
28	Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 568-576.	2.1	110
29	HIV infection and incidence of ischemic stroke. Aids, 2014, 28, 1911-1919.	2.2	108
30	HIV infection, aging, and immune function. Current Opinion in Oncology, 2012, 24, 506-516.	2.4	105
31	Declining Relative Risk for Myocardial Infarction Among HIV-Positive Compared With HIV-Negative Individuals With Access to Care. Clinical Infectious Diseases, 2015, 60, 1278-1280.	5.8	105
32	Survival among HIV-Infected and HIV-Uninfected Individuals with Common Non–AIDS-Defining Cancers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1167-1173.	2.5	101
33	Cohort profile: Study of Transition, Outcomes and Gender (STRONG) to assess health status of transgender people. BMJ Open, 2017, 7, e018121.	1.9	100
34	Prescription Long-term Opioid Use in HIV-infected Patients. Clinical Journal of Pain, 2012, 28, 39-46.	1.9	95
35	Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. Lancet HIV,the, 2019, 6, e93-e104.	4.7	94
36	Response to Newly Prescribed Lipid-Lowering Therapy in Patients With and Without HIV Infection. Annals of Internal Medicine, 2009, 150, 301.	3.9	92

#	Article	IF	CITATIONS
37	Virologic and immunologic response to HAART, by age and regimen class. Aids, 2010, 24, 2469-2479.	2.2	92
38	Clinical Course of Recurrent Respiratory Papillomatosis in Danish Children. JAMA Otolaryngology, 2004, 130, 711.	1.2	91
39	Trends and Disparities in Antiretroviral Therapy Initiation and Virologic Suppression Among Newly Treatment-Eligible HIV-Infected Individuals in North America, 2001–2009. Clinical Infectious Diseases, 2013, 56, 1174-1182.	5.8	90
40	Impact of Age on Retention in Care and Viral Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 413-419.	2.1	89
41	Oral Leukoplakia and Risk of Progression to Oral Cancer: A Population-Based Cohort Study. Journal of the National Cancer Institute, 2020, 112, 1047-1054.	6.3	88
42	AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Current Opinion in Oncology, 2007, 19, 446-451.	2.4	84
43	The Impact of HIV Infection and Immunodeficiency on Human Papillomavirus Type 6 or 11 Infection and on Genital Warts. Sexually Transmitted Diseases, 2002, 29, 427-435.	1.7	78
44	Race/Ethnicity and Risk of AIDS and Death Among HIV-infected Patients with Access to Care. Journal of General Internal Medicine, 2009, 24, 1065-1072.	2.6	77
45	Incidence and risk factors of HPV-related and HPV-unrelated Head and Neck Squamous Cell Carcinoma in HIV-infected individuals. Oral Oncology, 2014, 50, 1169-1176.	1.5	77
46	Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 413-419.	2.1	75
47	CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?. AIDS Research and Therapy, 2010, 7, 45.	1.7	73
48	Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America. Clinical Infectious Diseases, 2017, 65, 636-643.	5.8	67
49	Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk. Current Opinion in HIV and AIDS, 2014, 9, 34-40.	3.8	64
50	Cancer Screening in Patients Infected with HIV. Current HIV/AIDS Reports, 2011, 8, 142-152.	3.1	63
51	HIV Infection, Immunosuppression, and Age at Diagnosis of Non-AIDS-Defining Cancers. Clinical Infectious Diseases, 2016, 64, ciw764.	5.8	63
52	Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. Clinical Infectious Diseases, 2016, 63, ciw531.	5.8	60
53	Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor–Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada. Clinical Infectious Diseases, 2021, 73, e2234-e2242.	5.8	59
54	Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. Aids, 2012, 26, 2223-2231.	2.2	58

#	Article	IF	CITATIONS
55	Association of Multiple Primary Skin Cancers With Human Immunodeficiency Virus Infection, CD4 Count, and Viral Load. JAMA Dermatology, 2017, 153, 892.	4.1	57
56	Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. Aids, 2010, 24, 1765-1770.	2.2	55
57	Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population. Public Health Reports, 2018, 133, 452-460.	2.5	54
58	Prevalence of Clinical Symptoms Associated with Highly Active Antiretroviral Therapy in the Women's Interagency HIV Study. Clinical Infectious Diseases, 2004, 39, 717-724.	5.8	52
59	Non-AIDS-Defining Malignancies in the HIV-Infected Population. Current Infectious Disease Reports, 2014, 16, 406.	3.0	51
60	Determination of Optimized Multidisciplinary Care Team for Maximal Antiretroviral Therapy Adherence. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 183-190.	2.1	49
61	Characterization of HIV Preexposure Prophylaxis Use Behaviors and HIV Incidence Among US Adults in an Integrated Health Care System. JAMA Network Open, 2021, 4, e2122692.	5.9	47
62	Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study. Lancet HIV,the, 2019, 6, e240-e249.	4.7	46
63	Barriers to preexposure prophylaxis use among individuals with recently acquired HIV infection in Northern California. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 536-544.	1.2	45
64	Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study. The Lancet Child and Adolescent Health, 2018, 2, 707-714.	5.6	44
65	Effectiveness of highly-active antiretroviral therapy by race/ethnicity. Aids, 2006, 20, 1531-1538.	2.2	43
66	Cancer burden attributable to cigarette smoking among HIV-infected people in North America. Aids, 2018, 32, 513-521.	2,2	42
67	Discontinuation of potent antiretroviral therapy: predictive value of and impact on CD4 cell counts and HIV RNA levels. Aids, 2001, 15, 2101-2108.	2.2	38
68	Epstein-Barr Virus Infection and Expression of B-cell Oncogenic Markers in HIV-Related Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2012, 18, 4702-4712.	7.0	38
69	Prostate Cancer Incidence and Prostate-Specific Antigen Testing Among HIV-Positive and HIV-Negative Men. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 495-502.	2.1	38
70	Disparities in Uptake of HIV Preexposure Prophylaxis in a Large Integrated Health Care System. American Journal of Public Health, 2016, 106, e2-e3.	2.7	38
71	Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 382-390.	2.1	37
72	Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C. JAMA Network Open, 2019, 2, e194765.	5.9	37

#	Article	IF	CITATIONS
73	Benefits and harms of lung cancer screening in HIV-infected individuals with CD4+ cell count at least 500 cells/ \hat{l}^{1} /4l. Aids, 2018, 32, 1333-1342.	2.2	35
74	Leukoplakia, Oral Cavity Cancer Risk, and Cancer Survival in the U.S. Elderly. Cancer Prevention Research, 2015, 8, 857-863.	1.5	33
75	Interventions to Reduce Unhealthy Alcohol Use among Primary Care Patients with HIV: the Health and Motivation Randomized Clinical Trial. Journal of General Internal Medicine, 2019, 34, 2054-2061.	2.6	33
76	Age and Racial/Ethnic Differences in the Prevalence of Reported Symptoms in Human Immunodeficiency Virus-Infected Persons on Antiretroviral Therapy. Journal of Pain and Symptom Management, 2009, 38, 197-207.	1.2	32
77	Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model. American Journal of Epidemiology, 2019, 188, 2097-2109.	3.4	32
78	HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons. Aids, 2011, 25, 1771-1777.	2.2	31
79	HIV Quality Performance Measures in a Large Integrated Health Care System. AIDS Patient Care and STDs, 2011, 25, 21-28.	2.5	31
80	Mortality Among Persons Entering HIV Care Compared With the General U.S. Population. Annals of Internal Medicine, 2021, 174, 1197-1206.	3.9	31
81	Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada. Clinical Infectious Diseases, 2020, 70, 1176-1185.	5.8	27
82	Differences in Response to Antiretroviral Therapy by Sex and Hepatitis C Infection Status. AIDS Patient Care and STDs, 2015, 29, 370-378.	2.5	26
83	CD4/CD8 Ratio and Cancer Risk Among Adults With HIV. Journal of the National Cancer Institute, 2022, 114, 854-862.	6.3	26
84	Serological Detection of Human Papillomavirus Type 16 Infection in Human Immunodeficiency Virus (HIV)-Positive and High-Risk HIV-Negative Women. Vaccine Journal, 2006, 13, 511-519.	3.1	23
85	Invasive Pneumococcal Disease Among HIV-Infected and HIV-Uninfected Adults in a Large Integrated Healthcare System. AIDS Patient Care and STDs, 2016, 30, 463-470.	2.5	23
86	Immunodeficiency, AIDS-related pneumonia, and risk of lung cancer among HIV-infected individuals. Aids, 2017, 31, 989-993.	2.2	23
87	Laboratory Measures as Proxies for Primary Care Encounters: Implications for Quantifying Clinical Retention Among HIV-Infected Adults in North America. American Journal of Epidemiology, 2015, 182, 952-960.	3.4	22
88	Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2021, 72, 1900-1909.	5.8	22
89	Antiretroviral Therapy Adherence and Use of an Electronic Shared Medical Record Among People Living with HIV. AIDS and Behavior, 2015, 19, 177-185.	2.7	21
90	Do antiretrovirals reduce the risk of non-AIDS-defining malignancies?. Current Opinion in HIV and AIDS, 2009, 4, 42-51.	3.8	20

#	Article	IF	Citations
91	Adverse childhood experiences, mental health, substance use, and HIV-related outcomes among persons with HIV. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 1241-1249.	1.2	19
92	Influence of Prior Antiretroviral Experience on Adherence and Responses to New Highly Active Antiretroviral Therapy Regimens. AIDS Patient Care and STDs, 2008, 22, 301-312.	2.5	18
93	Human Immunodeficiency Virus (HIV)– and Non-HIV–Associated Immunosuppression and Risk of Cervical Neoplasia. Obstetrics and Gynecology, 2018, 131, 47-55.	2.4	18
94	Efficacy and Safety of Ritonavir-Boosted and Unboosted Atazanavir Among Antiretroviral-Na \tilde{A} -ve Patients. HIV Clinical Trials, 2008, 9, 367-374.	2.0	17
95	Implementation and Operational Research: Affordable Care Act Implementation in a California Health Care System Leads to Growth in HIV-Positive Patient Enrollment and Changes in Patient Characteristics. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, e76-e82.	2.1	17
96	Brief Report: Cutaneous Melanoma Risk Among People With HIV in the United States and Canada. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 499-504.	2.1	17
97	Smoking and cessation treatment among persons with and without HIV in a U.S. integrated health system. Drug and Alcohol Dependence, 2020, 213, 108128.	3.2	17
98	Factors associated with hazardous alcohol use and motivation to reduce drinking among HIV primary care patients: Baseline findings from the Health & Motivation study. Addictive Behaviors, 2018, 84, 110-117.	3.0	16
99	Acceptability of highâ€resolution anoscopy for anal cancer screening in <scp>HIV</scp> â€infected patients. HIV Medicine, 2018, 19, 716-723.	2.2	16
100	Early Adopters of Event-driven Human Immunodeficiency Virus Pre-exposure Prophylaxis in a Large Healthcare System in San Francisco. Clinical Infectious Diseases, 2020, 71, 2710-2712.	5.8	16
101	Is There a Link Between Hormone Use and Diabetes Incidence in Transgender People? Data From the STRONG Cohort. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1549-e1557.	3.6	16
102	Agreement between medical records and self-reports: Implications for transgender health research. Reviews in Endocrine and Metabolic Disorders, 2018, 19, 263-269.	5.7	15
103	Longitudinal Changes in Hematologic Parameters Among Transgender People Receiving Hormone Therapy. Journal of the Endocrine Society, 2020, 4, bvaa119.	0.2	15
104	Changes in Days of Unhealthy Alcohol Use and Antiretroviral Therapy Adherence, HIV RNA Levels, and Condomless Sex: A Secondary Analysis of Clinical Trial Data. AIDS and Behavior, 2020, 24, 1784-1792.	2.7	14
105	No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients. Clinical Gastroenterology and Hepatology, 2018, 16, 927-935.	4.4	13
106	The relationship of smoking and unhealthy alcohol use to the HIV care continuum among people with HIV in an integrated health care system. Drug and Alcohol Dependence, 2021, 219, 108481.	3.2	13
107	Use of web-based shared medical records among patients with HIV. American Journal of Managed Care, 2013, 19, e114-24.	1.1	13
108	Demographic, Insurance, and Health Characteristics of Newly Enrolled HIV-Positive Patients After Implementation of the Affordable Care Act in California. American Journal of Public Health, 2016, 106, 1211-1213.	2.7	12

#	Article	IF	Citations
109	Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 421-429.	2.1	12
110	Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare system. International Journal of STD and AIDS, 2019, 30, 689-695.	1.1	12
111	Hospitalization Rates and Causes Among Persons With HIV in the United States and Canada, 2005–2015. Journal of Infectious Diseases, 2021, 223, 2113-2123.	4.0	12
112	Risk Factors for Short-Term Virologic Outcomes Among HIV-Infected Patients Undergoing Regimen Switch of Combination Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2012, 28, 1630-1636.	1.1	10
113	Mental and Physical Quality of Life by Age Groups in People Living With HIV. Journal of the Association of Nurses in AIDS Care, 2019, 30, 500-510.	1.0	10
114	Missing Data on the Estimation of the Prevalence of Accumulated Human Immunodeficiency Virus Drug Resistance in Patients Treated With Antiretroviral Drugs in North America. American Journal of Epidemiology, 2011, 174, 727-735.	3.4	9
115	Short-term outcomes for lung cancer resection surgery in HIV infection. Aids, 2019, 33, 1353-1360.	2.2	9
116	Association of raltegravir use with long-term health outcomes in HIV-infected patients: an observational post-licensure safety study in a large integrated healthcare system. HIV Clinical Trials, 2018, 19, 177-187.	2.0	8
117	Health Systemâ€Based Unhealthy Alcohol Use Screening and Treatment Comparing Demographically Matched Participants With and Without HIV. Alcoholism: Clinical and Experimental Research, 2020, 44, 2545-2554.	2.4	8
118	HIV Stigma and Its Associations with Longitudinal Health Outcomes Among Persons Living with HIV with a History of Unhealthy Alcohol Use. AIDS and Behavior, 2021, 25, 215-224.	2.7	8
119	Cancer in People with and without Hepatitis C Virus Infection: Comparison of Risk Before and After Introduction of Direct-Acting Antivirals. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2188-2196.	2. 5	8
120	Early Outcomes of a High-Resolution Anoscopy-Based Anal Cancer Screening Program Among People With HIV Enrolled in an Integrated Health Care System. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 292-299.	2.1	7
121	Effectiveness of â€~catch-up' human papillomavirus vaccination to prevent cervical neoplasia in immunosuppressed and non-immunosuppressed women. Vaccine, 2020, 38, 4520-4523.	3.8	7
122	Influence of provider experience on antiretroviral adherence and viral suppression. HIV/AIDS - Research and Palliative Care, 2012, 4, 125.	0.8	6
123	Colorectal Cancer Screening in People With and Without HIV in an Integrated Health Care Setting. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 284-291.	2.1	6
124	Clinical Effectiveness of Integrase Strand Transfer Inhibitor–Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada. Clinical Infectious Diseases, 2020, 73, e1408-e1414.	5.8	6
125	Life Expectancy of Insured People With and Without Hepatitis C Virus Infection, 2007–2017. Open Forum Infectious Diseases, 2020, 7, ofaa044.	0.9	6
126	Recurrence after hospitalization for acute coronary syndrome among <scp>HIV</scp> â€infected and <scp>HIV</scp> â€uninfected individuals. HIV Medicine, 2019, 20, 19-26.	2.2	5

#	Article	IF	CITATIONS
127	Racial and Ethnic Differences in Substance Use Diagnoses, Comorbid Psychiatric Disorders, and Treatment Initiation among HIV-Positive and HIV-Negative Women in an Integrated Health Plan. Journal of Psychoactive Drugs, 2016, 48, 377-383.	1.7	4
128	New insights into the role of HIV infection on cancer risk. Lancet Oncology, The, 2009, 10, 1133-1134.	10.7	3
129	Does Human Papillomavirus Cause Esophageal Adenocarcinoma?. Clinical Gastroenterology and Hepatology, 2015, 13, 1369-1370.	4.4	3
130	Impact of Alternative Encounter Types on HIV Viral Suppression Rates in an Integrated Health System. AIDS Patient Care and STDs, 2018, 32, 425-431.	2.5	3
131	Health care utilization and HIV clinical outcomes among newly enrolled patients following Affordable Care Act implementation in a California integrated health system: a longitudinal study. BMC Health Services Research, 2020, 20, 1030.	2.2	3
132	Current and Past Immunodeficiency Are Associated With Higher Hospitalization Rates Among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years. Journal of Infectious Diseases, 2021, 224, 657-666.	4.0	3
133	Development and Calibration of a Mathematical Model of Anal Carcinogenesis for High-Risk HIV-Infected Men. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 10-19.	2.1	2
134	Treatment for alcohol use disorder among persons with and without HIV in a clinical care setting in the United States. Drug and Alcohol Dependence, 2021, 229, 109110.	3.2	2
135	Age group differences in substance use, social support, and physical and mental health concerns among people living with HIV two years after receiving primary care-based alcohol treatment. Aging and Mental Health, 2023, 27, 1011-1019.	2.8	2
136	Effect of Body Weight and Other Metabolic Factors on Risk of Non-Small Cell Lung Cancer among Veterans with HIV and a History of Smoking. Cancers, 2020, 12, 3809.	3.7	1
137	Association of the VACS Index with hospitalization among people with HIV in the NA-ACCORD. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, Publish Ahead of Print, 9-18.	2.1	1
138	The HIV preexposure prophylaxis (PrEP) continuum of care among transgender individuals in an integrated healthcare system. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, Publish Ahead of Print, .	2.1	1
139	Human immunodeficiency virus infection and risks of morbidity and death in adults with incident heart failure. European Heart Journal Open, $2021, 1, .$	2.3	1
140	Hepatitis C coinfection and extrahepatic cancer incidence among people living with HIV. HIV Medicine, 2021, , .	2.2	1
141	Response to Brandt, Bednarz-Knoll, Kleinheinz et al. Journal of the National Cancer Institute, 2020, 112, 970-971.	6.3	0
142	Comparative Outcomes for Mature T and NK/T-cell Lymphomas in People with and without HIV and to AIDS-Defining Lymphomas. Blood Advances, 2022, , .	5.2	0